Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for participants with large b-cell lymphoma (DLBCL) or follicular lymphoma (FL). Participants will receive siltuximab, prior to the injection of epcoritamab. Epcoritamab is administered in 28 day cycles for one year. After this injection, the physician will continue to watch participants for side effects and follow the condition for a minimum of 60 days.

Trial Details

NCT ID
NCT06447376
Phase
PHASE1
Sponsor
Taylor Brooks
Status
RECRUITING
Cancer Type
Hodgkin Lymphoma Lymphoma
Interventions
  • Siltuximab
  • Epcoritamab
  • Gemcitabine and oxaliplatin
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Adults 18 years of age and older
  • Diagnosis of non-Hodgkin lymphoma.
  • DLBCL (including high grade B cell lymphoma and follicular lymphoma grade 3B and transformed follicular lymphoma) treated with at least 2 lines of …
  • FL grade 1-3A previously treated with at least 2 lines of systemic antineoplastic therapy, including at least 1 anti-CD20 monoclonal antibody - con…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hodgkin Lymphoma Lymphoma Trials on Trialify →